A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2)

Web Site

Search this article

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association / International Gastric Cancer Association, Japanese Gastric Cancer Association [編]

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association / International Gastric Cancer Association, Japanese Gastric Cancer Association [編] 22 (2), 344-354, 2019

Tokyo : Springer Japan

Back to top